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Introduction: Accurate, cost-effective methods for testing anaplas-
tic lymphoma kinase gene rearrangement (ALK) are needed to
select patients with non-small cell lung carcinoma for ALK-inhibitor
therapy. Fluorescent in situ hybridization (FISH) is used to detect
ALK, but it is expensive and not routinely available. We explored
the potential of an immunohistochemistry (IHC) scoring system as
an affordable, accessible approach.
Methods: One hundred one samples were obtained from an en-
riched cohort of never-smokers with adenocarcinoma from the
Mayo Clinic Lung Cancer Cohort. IHC was performed using the
ALK1 monoclonal antibody with ADVANCE detection system
(Dako) and FISH with dual-color, break-apart probe (Abbott Mo-
lecular) on formalin-fixed, paraffin-embedded tissue.
Results: Cases were assessed as IHC score 0 (no staining; n  69),
1 (faint cytoplasmic staining, n  21), 2 (moderate, smooth
cytoplasmic staining; n  3), or 3 (intense, granular cytoplasmic
staining in 10% of tumor cells; n  8). All IHC 3 cases were
FISH, whereas 1 of 3 IHC 2 and 1 of 21 IHC 1 cases were
FISH. All 69 IHC 0 cases were FISH. Considering FISH a
gold-standard reference in this study, sensitivity and specificity of
IHC were 90 and 97.8%, respectively, when 2 and 3 were
regarded as IHC positive and 0 and 1 as IHC negative.
Conclusions: IHC scoring correlates with FISH and may be a useful
algorithm in testing ALK by FISH in non-small cell lung carci-
noma, similar to human epidermal growth factor-2 testing in breast
cancer. Further study is needed to validate this approach.
Key Words: Immunohistochemistry, Fluorescent in situ hybridiza-
tion, Anaplastic lymphoma kinase, Non-small cell lung carcinoma,
Adenocarcinoma.
(J Thorac Oncol. 2011;6: 459–465)
IAnaplastic lymphoma kinase (ALK) encodes a receptortyrosine kinase that is normally expressed only in select
neuronal cell types.1 ALK has been shown to be constitutively
expressed through a point mutation in a subset of neuroblas-
tomas2–5 or fusion oncogene formation by translocation in-
volving the chromosome 2p in anaplastic large cell lym-
phoma (ALCL)6,7 and inflammatory myofibroblastic tumor
(IMT).8 Recently, ALK gene rearrangement (ALK) was also
identified in non-small cell lung carcinomas (NSCLCs; pre-
dominantly adenocarcinomas) as an inversion in chromosome
2p with or without interstitial deletion, resulting in the echi-
noderm microtubule-associated protein-like 4 (EML4)–ALK
fusion product.7 This product leads to the expression of a
chimeric tyrosine kinase, in which the N-terminal half of
EML4 is fused to the intracellular kinase domain of ALK.7,9
The EML4–ALK protein possesses potent oncogenic activity
both in vitro and in vivo. This activity can be effectively
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blocked by small-molecule inhibitors that target ALK, which
supports a role for EML4–ALK as a key driver of lung
tumorigenesis in a subset of NSCLCs7,9; thus, this fusion
oncogene represents one of the newest molecular targets in
NSCLC.
In a phase I clinical trial, investigational drug crizotinib
(PF-02341066), an ALK inhibitor, showed an objective re-
sponse rate of 57% and disease control rate of 87% at 8 weeks
in patients with NSCLC whose tumors had a rearrangement
of ALK.10 Therefore, it is critical to identify patients with this
abnormality correctly. A true gold standard for ALK has not
been established, although fluorescent in situ hybridization
(FISH) has been used to detect ALK tumors in clinical trials
and in a previous study of clinical features and outcomes of
patients with ALK NSCLC.11 However, FISH is relatively
expensive and not widely available. Immunohistochemistry
(IHC) is relatively inexpensive, faster, and performed rou-
tinely in most diagnostic laboratories; thus, it could serve as
a practical tool for clinicians.
We hypothesized that IHC can be used to screen for
ALK with confirmatory FISH based on IHC scoring, a
system well established in human epidermal growth factor
receptor-2 (HER2) testing for patients with breast cancer.12
We report an IHC scoring system based on a routine IHC
method with a widely used, commercially available antibody
for ALK. Such a practical screening method, in combination
with a confirmatory test—in this case, FISH—might signifi-
cantly reduce the need to perform FISH to detect ALK
status in patients with NSCLC, thereby substantially decreas-
ing costs and turnaround times.
MATERIALS AND METHODS
Case Selection
The Mayo Clinic Lung Cancer Cohort was used to
identify patients for this retrospective study. Given the low
incidence of ALK reported in resected lung adenocarcino-
mas within a nonselected western population13 and that pre-
vious studies have reported that adenocarcinomas harboring
ALK tend to occur in never-smokers or light smokers,11,13,14
we enriched our cohort by including only never-smokers with
adenocarcinoma. A total of 101 patients met the selection
criteria and were included in this study.
Patients with adenocarcinoma who had never smoked,
and had a minimum of 1 year of follow-up medical records,
and banked tissue samples from surgical resections (com-
posed of wedge resection or more extensive surgeries), were
eligible for inclusion. Whole sections, not tissue microarrays,
were used in this study. All available slides from each case
were reviewed to verify the diagnosis and to select the
representative block containing most viable tumor cells by
two pathologists (E.S.Y. and M.C.A.). This study has been
approved by the institutional review board of the Mayo
Foundation.
Immunohistochemistry
Four-micron sections cut from formalin-fixed, paraffin-
embedded blocks were placed on charged slides, which were
then dried and melted in a 62°C oven for 20 minutes. Slides
were deparaffinized through xylenes and graded alcohols to
tap water, and heat-induced epitope retrieval was performed
by treating the slides in a Dako PT Link (Dako, Carpinteria,
CA), containing a solution of 1 mM ethylenediaminetet-
raacetic acid, pH 8.0, preheated to 97°C, for 30 minutes. All
remaining steps were performed at room temperature. Endog-
enous peroxidase was blocked by placing the slides in a 1:1
solution of 3% hydrogen peroxide:absolute methanol. Slides
were placed on the Dako Autostainer (Dako); primary anti-
body (mouse monoclonal ALK antibody, clone ALK1; Dako;
1:100 dilution) was applied and incubated for 30 minutes.
Antigen–antibody reaction was visualized by an enhanced
polymer-based detection system, ADVANCE (Dako), with
20-minute incubation for ADVANCE Link and 20-minute
incubation for ADVANCE horseradish peroxidase. Diamino-
benzidene (DAB; Dako) was employed for 5 minutes as the
chromogen. All slides were counterstained with hematoxylin,
dehydrated, and coverslipped for microscopic examination.
The positive control was from a known CD30-positive ALCL
case. The negative control was a mouse immunoglobulin G1
serum substitution for the primary antibody (ALK).
IHC Scoring
An IHC score was assigned to each case according to
the following criteria: 3, intense, granular cytoplasmic
staining; 2, moderate, smooth cytoplasmic staining; 1,
faint cytoplasmic staining in 10% of tumor cells; and 0, no
staining. IHC scoring was performed by two pathologists
(E.S.Y. and J.M.B.) before FISH testing. IHC score 3 cases
typically reveal widespread, although still patchy, easily dis-
cernable intense cytoplasmic positivity that shows a distinct
granular texture as depicted in Figure 1A. IHC score 2 cases
also show readily recognizable positivity but to a lesser extent
and with less intensity of staining than in score 3 cases. Score
2 cases do not reveal the granular texture seen in score 3 cases
but show more smooth or smudged staining (Figure 1B). In
score 1 cases, the observer typically struggles to determine
whether faint positivity represents a background stain or real
positivity, unlike the readily detectable staining of score 2
and 3 cases (Figure 1C). Score 0 cases do not show any
significant staining (Figure 1D). Consensus was established
by reviewing the slides together in the case of discrepant
scores, typically 1 versus 0. To evaluate the reproducibility
of our scoring system, two additional pathologists (A.C.R.
and J.J.M.) performed IHC scoring after a training session,
with typical examples of each score provided by the pathol-
ogist who devised the scoring scheme (E.S.Y.). E.S.Y. re-
peated the scoring along with the two additional pathologists
for intraobserver and interobserver reproducibility. The
kappa statistic was used for interobserver variability between
the findings of all three pathologists (E.S.Y., A.C.R., and
J.J.M.) and intraobserver variability within the findings of a
single pathologist (E.S.Y.).
FISH for ALK Rearrangement
Interphase molecular cytogenetic studies using a com-
mercially available ALK probe (Vysis LSI ALK Dual Color,
Break Apart Rearrangement Probe; Abbott Molecular, Ab-
bott Park, IL) were performed on 4-m paraffin-embedded
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sections that were deparaffinized twice in xylene for 15
minutes, dehydrated twice in 100% ethylic alcohol for
5 minutes, and treated with 10 mmol/L citric acid for 10
minutes in a humid microwave. Tissue sections were then
transferred to 37°C 2 standard saline citrate (SSC) for 5
minutes, and protein was digested with Digest All-3
(Zymed, San Francisco, CA). After brief washing in 1
phosphate-buffered saline, the slides were sequentially
dehydrated in alcohol (70, 85, and 100%) and air dried at
room temperature. Five microliters of ALK probe were
diluted per manufacturer’s instructions and added to the
tissue sections. Slides were denatured at 80°C for 5 min-
utes, and probe hybridization was carried out overnight in
a humidified chamber at 37°C. Tissue sections were
washed in 0.1% NP40/2 SSC at 76°C for 4 minutes and
then washed in 0.1% NP40/2 SSC at room temperature
for 1 minute. Slides were mounted in VECTASHIELD
Mounting Medium (Vector Laboratories, Burlingame, CA)
with 1.5 g/ml of 4,6-diamidino-2-phenylindole.
FISH Interpretation
FISH for ALK locus rearrangement was considered
positive if 15% or more tumor cells counted showed a split
signal of the fluorescent probes flanking the ALK locus
(Figure 2). One hundred cells were analyzed in each case. All
FISH interpretation was done in a separate laboratory without
the knowledge of IHC results for ALK. Because the rear-
rangement of the ALK locus in this group of tumors is often
because of a paracentric inversion of approximately 12.4 Mb
(fusion with the EML4 gene on chromosome 2p21), internal
and external normal controls were used to estimate whether
the distance between the separated signals was larger than the
distance that would be expected for stochastic separation of
these signals in tissues that lack ALK rearrangement. This
distance was estimated using the 1 signal size diameter as a
reference. On the basis of a series of control experiments, we
confirmed that probe separation distances larger than 8 Mb
can be readily detectable on paraffin-embedded tissues with
high sensitivity (95.6%) and specificity (97.6%).
The ALK probe consists of one red and one green
signals that appear as yellow when fused in normal cells as
opposed to two separate signals in abnormal cells. All pat-
terns of red and green signals encountered in each of the 100
FIGURE 1. Score 3 showing intense,
granular cytoplasmic staining (A);
score 2 showing moderate, smooth
(without the apparent granularity
seen in score 3) cytoplasmic staining
(B); score 1 showing faint, barely dis-
cernable cytoplasmic staining (C); and
score 0 showing no staining (D). Ana-
plastic lymphoma kinase immunohis-
tochemical staining, 200 original
magnification.
FIGURE 2. Dual-color, break-apart fluorescent in situ hy-
bridization was performed on paraffin-embedded tissues us-
ing the commercially available anaplastic lymphoma kinase
(ALK) probe (Vysis LSI ALK Dual Color, Break Apart Rear-
rangement Probe; Abbott Molecular). The centromeric
(green) and telomeric (red) flank the ALK locus. Splitting of
the red and green signals indicates ALK rearrangement.
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cells counted were recorded. We considered several different
patterns of split signals as abnormal, and the number of
abnormal cells was summed to generate the final count for
determining FISH status. A threshold was set for each abnor-
mal pattern at 5 or 10, and the number of abnormal cells was
added if the number was above the threshold. In addition to
the classic break-apart pattern (BAP) showing one fusion,
one red, and one green signal in a cell, we also considered the
following patterns as abnormal split signals: one fusion 
one red signal only, one fusion  one green signal only, one
to two fusion signals  two to three green signals  two to
three red signals, one red  one green signal only (without
fusion signal), one to two fusions  one to four red signals,
two fusions  one BAP, three fusions  one BAP, and two
to four fusions one to two red signals. We set the threshold
for patterns to be considered abnormal at 10% for classic
BAP pattern and for one fusion one red or green signal, and
at 5% for the rest of patterns listed earlier. Then, we summed
the numbers that were above the threshold, and this was
regarded as FISH positive if it was 15 or higher. Represen-
tative data on positive and negative cases for FISH are listed
in Supplementary Table 1 (Supplemental Digital Content 1,
http://links.lww.com/JTO/A63).
RESULTS
We found 10 (9.9%) ALK cases by FISH in our
enriched cohort of never-smokers with adenocarcinoma
(higher than reported in resected lung adenocarcinomas in an
unselected cohort of western patients [1 of 227 cases;
0.45%]13). The mean age of the 10 patients ALK by FISH
was 56 years (range 36–76 years). Five of the 10 patients
were men. Three patients had stage I disease, one stage II,
five stage III, and one stage IV. A more detailed clinicopath-
ologic study, including examination of clinical outcomes in
ALK versus carefully matched ALK– patients, is in progress
with additional patients from the ongoing Mayo Clinic Lung
Cancer Cohort, results of which will be reported separately.
IHC score 3 was found in 8 cases, 2 in 3 cases, 1
in 21 cases, and 0 in 69 cases. All 8 IHC 3 cases were
ALK by FISH, whereas 1 of 3 IHC 2 and 1 of 21 IHC 1
cases were ALK by FISH. All 69 IHC 0 cases were negative
for ALK by FISH. These findings are summarized in Table 1.
IHC 3 and 2 cases demonstrated readily apprecia-
ble cytoplasmic positivity (Figures 1A, B) and were thus
regarded IHC positive. Conversely, IHC 1 cases showed
only faint positivity (Figure 1C) and were thus regarded IHC
negative, as were IHC 0 cases without any discernable stain-
ing (Figure 1D). With this definition, there were two IHC-
positive cases (both IHC 2) that were negative for ALK
rearrangement by FISH, resulting in 97.8% specificity of IHC
positivity for ALK. However, all IHC 3 cases were
ALK. One of 21 IHC 1 cases was ALK by FISH, giving
90% sensitivity of IHC for ALK. FISH on all 69 IHC 0
cases was also negative for ALK rearrangement.
The weighted kappa scores between E.S.Y. (original
scorer) and A.C.R. or J.J.M. were 0.55 (95% confidence
interval [CI] 0.40–0.70) and 0.50 (95% CI 0.35–0.64), re-
spectively. Intraclass correlation in these three observers was
0.93 (95% CI 0.86–0.93). The weighted kappa between
A.C.R. and J.J.M. was 0.80 (95% CI 0.72–0.89). The
weighted kappa between the initial scores and the repeat
scores by the reevaluation of E.S.Y. was 0.82 (95% CI
0.72–0.93). IHC scores by all observers on all cases along
with FISH results are listed in Supplemental Table 2 (Sup-
plemental Digital Content 2, http://links.lww.com/JTO/A64).
DISCUSSION
We performed this study to evaluate the potential role
of IHC as a detection or screening method for ALK. We
refined the IHC results by giving a score in each case and
correlated this with ALK status by FISH in all cases. There
was virtually no background staining in our IHC, consistent
with the biologic fact that there is no constitutive ALK
expression in the nonneoplastic lung tissue.7
A true gold standard to determine ALK has not been
established. Various molecular techniques including reverse-
transcriptase polymerase chain reaction, direct sequencing,
and FISH have been used in previous studies (Table 2). FISH
could be a method of choice, because it is relatively simpler
than other molecular techniques and has the ability of directly
visualizing translocation with appropriate probes for the ALK
gene. However, FISH has its own pitfalls; interpretation of
FISH for ALK in NSCLC tends to be more difficult than in
ALCL or IMT because ALK in NSCLC is an intrachromo-
somal rearrangement, resulting in a relatively close separa-
tion of the break-apart probes, as shown in Figure 2. Rodig et
al.13 have also pointed out that FISH alone as initial screening
did not detect all cases with ALK. Previous studies11,13,16
used a cutoff value of 15% or more tumor cells to be
abnormal for FISH positivity. We also used 15% as the cutoff
for FISH positivity among the 100 cells counted. However,
none of the previous studies specified the number of tumor
cells that they counted.11,13,16 Most previous studies did not
systematically perform IHC with other molecular techniques.
Rather, they either performed IHC only on the ALK cases
by a molecular technique or did molecular confirmation only
on the IHC-positive cases, which precludes the assessment of
sensitivity and specificity. In a previous study,15 we used the
same IHC technique as in this study but interpreted results
only as positive or negative without scoring. Among 335
nonselected cases of NSCLC, there were 6 IHC-positive
cases (IHC score 2 or 3 according to our current scoring
criteria), all of which were positive for ALK by FISH. The
specificity and sensitivity of IHC positivity for ALK could
not be determined, because we did not perform FISH in all
IHC-negative cases (IHC score 0 and 1 according to our
current scoring criteria). However, eight randomly selected
TABLE 1. Correlation of IHC and FISH
IHC
Score 3
IHC
Score 2
IHC
Score 1
IHC
Score 0
FISH (n  10) 8 1 1 0
FISH (n  91) 0 2 20 69
IHC, immunohistochemistry; FISH, fluorescent in situ hybridization.
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IHC-negative tumors were negative for ALK rearrange-
ment by FISH in that study. Furthermore, 35 adenocarci-
noma cases among the total 335 NSCLCs had available
gene expression profile data, and IHC results were 100%
concordant with the gene expression profile. Two cases
with transcriptional up-regulation of ALK were positive for
ALK by IHC, whereas the remaining 33 cases were nega-
tive for ALK by IHC.15
TABLE 2. ALK IHC Methods and Results in the Literature
Author
Tissue Type/
Section
Antibody
Source Clone Dilution
Pretreatment/
Detection
Method
Gold
Standard
for ALK Sensitivity Specificity
This study Paraffin/whole
section
Dako ALK1 1:100 HIER with EDTA
(pH 8.0), in
Dako PT link;
ADVANCE
(Dako)
FISH 90.0% 97.8%
Boland et al.15 Paraffin/whole
section
Dako ALK1 1:100 HIER with EDTA
(pH 8.0), in
Dako PT link;
ADVANCE
(Dako)
FISH, RT-PCR,
gene
expression
profiling
100%a (tested
in 40 of
335 cases)
100%
Rodig et al.13 Paraffin/TMA Dako ALK1 1:2 HIER with EDTA
(pH 8.0), in
pressure cooker
(Decloaking
Chamber Biocare
Medical); tyramide
amplification and
EnVision (Dako)
FISH 80% 100%
Mino-Kenudson
et al.16
Paraffin/mostly
TMA (116
of 153 cases)
Dako for ALK1,
Cell Signaling
Technology
(Danvers, MA)
for D5F3
ALK1,
D5F3
1:2 for ALK1,
1:100 for
D5F3
HIER with EDTA
(pH 8.0) in
pressure cooker
(Decloaking
Chamber Biocare
Medical),
EnVision (Dako)
FISH 67% with ALK1
antibody,
100% with
D5F3
antibody
97% with
ALK1
antibody,
99% with
D5F3
antibody
Wong et al.17 Paraffin/not
specified
Invitrogen
(Carlsbad,
CA)
Polyclonal 1:1000 HIER with citrate
(pH 6.0) in
microwave;
Dako HRP
complex, not
further specified
RT-PCR,
direct
sequencing
100% (tested
in 12 of 13
ALK cases
by molecular
methods)
N/A
Shaw et al.11 Paraffin/not
specified
Dako ALK1 N/A N/A FISH 100% N/A
Inamura et al.14 Paraffin/not
specified
Dako ALK1 1:20 HIER with Target
Retrieval Solution
(pH 9.0, Dako),
EnVision  DAB
system with
modificationb
Multiplex
RT-PCR
100% N/A
Takeuchi et al.18 Paraffin/not
specified
Abcam
(Cambridge,
UK) for
5A4, Dako
for ALK1
5A4 and
ALK1
1:50 HIER with Target
Retrieval system
(pH 9.0, Dako);
EnVision  DAB
and iAEP method
Inverse and
multiplex
RT-PCR
100% for
both
antibodies
100% for both
antibodies
Martelli et al.19 Paraffin/not
specified
Not specified
for ALK1
and ALKc,
Thermo Fisher
Scientific
(Fremont,
CA) for 5A4
ALK1,
ALKc,
5A4
Not specified HIER with citrate
(pH 6.0) or
EDTA (pH 8.0)
in microwave;
Dako-REAL,
alkaline-phosphatase/
RED detection
system
RT-PCR, FISH 0% tested 0% tested
(nontumor
tissue in
the section
stained)
a It was assumed that all ALK cases by FISH were positive for IHC (i.e., 100% sensitivity) based on the statement in the abstract that reads “EML4-ALK was identified by using
FISH for ALK rearrangements and was confirmed by immunohistochemistry.” It was not further elaborated in the Results section, however.
b In the Materials and Method section, authors stated that “Immune complexes were detected with the EnVision DAB system (Dako) with minor modifications” and cited the
study in press by Takeuchi et al. using iAEP method. Therefore, this study might have used the iAEP detection method as well.
HIER, heat-induced epitope retrieval; TMA, tissue microarray; HRP, horseradish peroxidase; iAEP, intercalated antibody-enhanced polymer; ALK, anaplastic lymphoma kinase;
IHC, immunohistochemistry; FISH, fluorescent in situ hybridization; EDTA, ethylenediaminetetraacetic acid; RT-PCR, reverse-transcriptase polymerase chain reaction.
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Previous studies have reported a difficulty in detecting
ALK fusion proteins by IHC, possibly due to a weak tran-
scriptional activity of the promoter-enhancer region of EML4
that drives the expression of EML4–ALK compared with that
of the nucleophosmin promoter involved in the expression of
the nucleophosmin–ALK fusion protein in ALCL.16,18 Our
protocol at Mayo and protocol of another group18 showed a
high sensitivity of ALK IHC using the polymer-enhanced
detection system. Mino-Kenudson et al.16 reported IHC with
a novel, highly sensitive antibody for detection of ALK lung
adenocarcinoma cases. However, this antibody is not com-
mercially available and has not been independently tested by
other researchers because of its limited availability. Mino-
Kenudson et al.16 applied different dilutions in ALCL and
lung adenocarcinoma cases, which would not be practical in
diagnostic laboratories; it will be cumbersome for technolo-
gists to apply different dilutions, requiring separate prepara-
tion of reagents, resulting in extra work and potential errors.
Also, it could be problematic to use different clones of an
antibody depending on the type of tumor; again, the extra step
of indicating the clone of an antibody in each case could be
a potential area of confusion or a cause of delay when omitted
at the time of initial request.
In our study, we used a monoclonal antibody (Dako clone
ALK1), one of the most commonly used, well-tested ALK
antibodies, at the same dilution as used in ALCL and IMT,
making its use more practical from a diagnostic laboratory
perspective. Our IHC method is based on a standard IHC
method for a routine diagnostic surgical pathology practice at
Mayo Clinic Rochester for other antibodies and for the ALK
antibody. Application of an enhanced polymer-based detection
system (ADVANCE) may be the only deviation from standard
laboratory methods that we have introduced. It has three steps,
one more than conventional two-step systems such as
EnVision (also marketed by Dako): (1) primary antibody
application, (2) ADVANCE Link (goat antimouse/rabbit IgG),
and (3) ADVANCE horseradish peroxidase, the enzyme-conju-
gated polymer backbone. According to the manufacturer, AD-
VANCE is at least five times more sensitive than EnVision,
which uses only two steps: primary antibody application and
subsequent enzyme-conjugated secondary antibody application.
Takeuchi et al.18 also reported that their intercalated
antibody-enhanced polymer method, a method similar to the
ADVANCE system we used, provided high sensitivity and
specificity for ALK status proven by a polymerase chain
reaction-based molecular technique (Table 2).
In breast cancer, IHC scoring for HER2 with the
algorithm for FISH has been widely used in selecting patients
for anti-HER2 therapy, with guidelines from the American
Society of Clinical Oncology/College of American Patholo-
gists.12 According to the current American Society of Clinical
Oncology/College of American Pathologists guidelines,12
IHC 2 is recommended to be confirmed by reflex FISH for
HER2 gene amplification, whereas HER2 IHC 0 or 1 can be
regarded as negative and 3 as positive without FISH.
Similarly, our IHC scoring system might be useful in evalu-
ating patients with NSCLC for ALK-inhibitor treatment,
which would significantly limit the need for FISH confirma-
tion and could reduce time and costs. The same algorithm
could possibly be used (i.e., reflex FISH for IHC 2 cases
only), given the consistency of ALK in IHC 3 and the low
frequency of ALK in IHC 1 and 0 cases (1 of 21 and none
of 69, respectively). An alternative algorithm can be consid-
ered to direct IHC 1 and IHC 2 cases for reflex FISH.
However, distinction of IHC 1 from IHC 0 may be subjec-
tive, which could pose a problem for an algorithm requiring
reflex FISH on IHC 1 cases; many negative cases might be
directed for FISH, which would decrease the time and cost
benefit. In the context of HER2 testing in breast cancer, some
IHC 1 and 0 cases have been found to be FISH positive
(seven of 100 and 3 of 100, respectively).6 Therefore, we feel
that the sensitivity of our IHC scoring would be acceptable to
use the former algorithm (i.e., reflex FISH for IHC 2 cases
only). Also, discretionary FISH testing can be performed
even on IHC 1 or 0 cases if a clinical suspicion for ALK
is high (e.g., younger age, nonsmoking status, signet-ring cell
features). Currently, we are testing more cases in an ongoing
clinicopathologic study drawing from the Mayo Lung Cancer
Cohort; ALK testing by IHC and FISH will be further
evaluated in these cases.
Our IHC scoring might be an inexpensive and accurate
screening method, by an algorithm for FISH confirmation, to
identify patients with ALK NSCLC who will benefit from
anticipated anti-ALK therapy. However, further study is
needed to confirm our results. Our IHC method used a
time-tested, reliable monoclonal ALK antibody and a sensi-
tive, automated detection system, both of which are commer-
cially available.
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